Secondary sulphonylurea failure: What pathogenesis is responsible?

British Journal of Biomedical Science

Volumn 60, Issue 1, 2003, Pages 9-13

  Chen, Yi Ni ^a   Chen, S Y ^a   Zeng, L J ^a   Ran, J M ^a   Xie, B ^a   Wu, M Y ^a   Wu, Y Z ^a  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

Author keywords

Insulin; Islets of Langerhans; Pancreatic beta cells; Proinsulin; Sulfonylurea compounds

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; PROINSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0344643408     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2003.11783670     Document Type: Article

References (18)

1. Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, ed. International textbook of diabetes mellitus. Chichester: Wiley, 1992: 745-72.
2. Groop LC, Pelkonen R, Koskinies S et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9(2): 129-33.
3. Rhodes JC, Alarcon C. What β-cell defect could lead to hyperproinsulinemia in NIDDM? Diabetes 1994, 43: 511-7.
4. Williams DRR, Byrne C, Clark PMS et al. Raised proinsulin is an early indicator of β-cell function. BMJ 1991; 303: 95-6.
5. Wareham NJ, Day NE, Byrne CD et al. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 1999; 22: 262-70.
6. Roder ME, Vestergard H, Denison B et al. Intact proinsulin and β-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999; 22: 609-14.
7. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46: 1725-32.
8. Davies MJ, Metcalfe J, Day JL et al. Effect of sulphonylurea therapy on plasma insulin, intact and 32-33 split proinsulin in subjects with type 2 diabetes mellitus. Diabetic Medicine 1994; 11: 293-8.
9. Van der W PS, Heini RJ. Characteristics of pancreatic beta-cell secretion in type 2 diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 2001; 52: 103-11.
10. Inoguchi T, Umeda F, Kakimoto M et al. Chronic sulphonylurea treatment and hyperglycemia render disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J 2000; 47: 763-70.
11. Chazan AC, Gomes MB. Gliclazide and bed time insulin are more efficient than insulin alone for type 2 diabetic patients with sulphonylurea secondary failure. Braz J Med Biol Res 2001; 34: 49-56.
12. Yan L, Cheng H, Zhong G et al. Different responses of ?-cell to glucagon and glucose in type 2 diabetic patients with secondary failure to glibenclamide. Chin J Endocrinol Metab 1998; 14: 309-11.
13. Groop LC, Schalin C, Franssla-Kaunki A et al. Characteristics of non-insulin-dependant diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-90.
14. Krentz AJ, Nattrass M. Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Diabetic Medicine 1996; 13: 30-9.
15. Yah L, Zhong G, Cheng H et al. Re-evaluation of the maximal dose of glibenclamide recommended in NIDDM patients. Chin J Endocrinol Metab 1997; 13: 30-3.
16. Hoffman SM, Kennedy E, Gonzale C et al. A prospective analysis of the Homa Model: the Mexico City diabetic study. Diabetes Care 1996; 19: 1138-41.
17. Temple RC, Carrington CA, Luzio SD et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989; 11: 293-5.
18. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-8